CP 112116

Drug Profile

CP 112116

Latest Information Update: 03 Jul 2000

Price : $50

At a glance

  • Originator Pfizer
  • Class Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 03 Jul 2000 Profile reviewed but no significant changes made
  • 06 Dec 1996 No-Development-Reported for Neurological disorders (Prevention) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top